Acute myeloid leukemia (AML) is a kind of malignant hematopoietic system disease
characterized by abnormal proliferation, poor cell differentiation, and infiltration of bone …

Background The majority of individuals with acute myeloid leukemia (AML) respond to initial
chemotherapy and achieve a complete remission, yet only a minority experience long-term …

Acute myeloid leukemia (AML) is an aggressive clonal disorder of hematopoietic stem cells
(HSCs) and primitive progenitors that blocks their myeloid differentiation, generating self …

Pediatric acute myeloid leukemia (pAML) is characterized by heterogeneous cellular
composition, driver alterations and prognosis. Characterization of this heterogeneity and …

Acute myeloid leukemia (AML) is a stem cell–driven malignant disease. There is evidence
that leukemic stem cells (LSC) interact with stem cell niches and outcompete hematopoietic …

Acute myeloid leukemia (AML) is a clonal disorder arising from hematopoietic myeloid
progenitors. Aberrantly activated tyrosine kinases (TK) are involved in leukemogenesis and …

RAS oncogene mutations frequently occur in acute myeloid leukaemia (AML), but the
prognostic significance of RAS mutations in AML is inconclusive. We searched the …

Numerous studies have been performed over the last decade to exploit the complexity of
genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML) …

Genetic and epigenetic aberrations contribute to the initiation and progression of acute
myeloid leukemia (AML). GFI1, a zinc-finger transcriptional repressor, exerts its function by …

Background Recently, we found that berberine (BBR) exerts anti-acute myeloid leukemia
activity, particularly toward high-risk and relapsed/refractory acute myeloid leukemia MV4-11 …